Evidence map›Paper›PMID 25191700›Full record

ArticlePloS one2014

Clinical significance of the CCR5delta32 allele in hepatitis C.

Isabelle Morard, Sophie Clément, Alexandra Calmy, Alessandra Mangia, Andrea Cerny, Andrea De Gottardi, Meri Gorgievski, Markus Heim, Raffaele Malinverni, Darius Moradpour and 6 more

Open access · goldAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Review
  3. A Study on the Association betweenAvicenna journal of medical biotechnology
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 10 institutions in 2 countries.

Isabelle MorardDivision of Gastroenterology and Hepatology, University Hospitals, Geneva, Switzerland.
Sophie ClémentDivision of Clinical Pathology, University Hospitals, Geneva, Switzerland.
Alexandra CalmyDivision of Infectious Diseases, University Hospitals, Geneva, Switzerland.
Alessandra MangiaLiver Unit, IRCCS "Casa Sollievo della Sofferenza," San Giovanni Rotondo, Italy.
Andrea CernyService of Hepatology, Clinica Moncucco, Lugano, Switzerland.
Andrea De GottardiDivision of Hepatology, University Hospital of Bern, Bern, Switzerland.
Meri GorgievskiDivision of Infectious Diseases, University Hospital of Bern, Bern, Switzerland.
Markus HeimDivision of Gastroenterology and Hepatology, University Hospitals of Basel, Basel, Switzerland.
Raffaele MalinverniDivision of Infectious Diseases, Pourtalès Hospital, Neuchâtel, Switzerland.
Darius MoradpourDivision of Gastroenterology and Hepatology, University Hospital and University of Lausanne, Lausanne, Switzerland.
Beat MüllhauptDivision of Gastroenterology and Hepatology, University Hospitals of Zurich, Zurich, Switzerland.
David SemelaDivision of Gastroenterology, Canton Hospital, St. Gall, Switzerland.
Stéphanie PascarellaDepartment of Pathology and Immunology, University of Geneva, Geneva, Switzerland.
Pierre-Yves BochudDivision of Infectious Diseases, University Hospital and University of Lausanne, Lausanne, Switzerland.
Franco NegroDivision of Gastroenterology and Hepatology, University Hospitals, Geneva, Switzerland; Division of Clinical Pathology, University Hospitals, Geneva, Switzerland.
Swiss Hepatitis C Cohort Study Group
University Hospital of Geneva · CHUniversity Hospital of Bern · CHUniversity of Lausanne · CHCasa Sollievo della Sofferenza · ITClinica Luganese Moncucco · CHHospital Neuchâtel · CHUniversity Hospital of Basel · CHUniversity Hospital of Zurich · CHUniversity of Geneva · CHUniversity of St. Gallen · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe CCR5 receptor, expressed on Th1 cells, may influence clinical outcomes of HCV infection. We explored a possible link between a CCR5 32-base deletion (CCR5delta32), resulting in the expression of a non-functioning receptor, and clinical outcomes of HCV infection.

methodsCCR5 and HCV-related phenotypes were analysed in 1,290 chronically infected patients and 160 patients with spontaneous clearance.

resultsCarriage of the CCR5delta32 allele was observed in 11% of spontaneous clearers compared to 17% of chronically infected patients (OR = 0.59, 95% CI interval 0.35-0.99, P = 0.047). Carriage of this allele also tended to be observed more frequently among patients with liver inflammation (19%) compared to those without inflammation (15%, OR = 1.38, 95% CI interval 0.99-1.95, P = 0.06). The CCR5delta32 was not associated with sustained virological response (P = 0.6), fibrosis stage (P = 0.8), or fibrosis progression rate (P = 0.4).

conclusionsThe CCR5delta32 allele appears to be associated with a decreased rate of spontaneous HCV eradication, but not with hepatitis progression or response to antiviral therapy.

Indexed as

AllelesHepacivirusMutationDisease ProgressionFemaleGenotypeHepatitis CHumansLiverMalePatient Outcome AssessmentPhenotypeReceptors, CCR5Receptors, CCR5

Identifiers

PMID25191700
PMCPMC4156365
OpenAlexW1995231957

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.